SELECT THERAPEUTICS 937075 vor KURSRALLYE!!! - 500 Beiträge pro Seite
eröffnet am 03.09.02 23:17:46 von
neuester Beitrag 28.10.02 15:50:50 von
neuester Beitrag 28.10.02 15:50:50 von
Beiträge: 12
ID: 628.436
ID: 628.436
Aufrufe heute: 0
Gesamt: 571
Gesamt: 571
Aktive User: 0
ISIN: US8162091008 · WKN: 937075
Heute allein +25% an einem solchen Tag!
Schaut Sie Euch mal an - Restrukturierung wurde bereits genehmigt!!!
Aktuell 0,15$ - könnten sehr schnell Richtung 0,3-0,5$ gehen!
MfG
Star Ikone 2
Die Meldung:
Select Therapeutics Inc. Receives Notification of American Stock Exchange Acceptance of
Plan of Compliance
BOSTON, Aug 1, 2002 /PRNewswire-FirstCall via COMTEX/ -- Select Therapeutics
Inc. (Amex: XZL), today announced that the American Stock Exchange ("AMEX" or
the "Exchange") has accepted Select`s plan of compliance and that the Company
has received a listing extension to regain compliance with AMEX`s listing
standards on or before December 31, 2003, subject to periodic review by the
Exchange.
On April 26, 2002, Select received notice from the AMEX Staff indicating that,
as of the date of the letter, the Company had fallen below the continued
listings standards of the Exchange due to stockholders equity below $2 million
dollars and sustained losses in two of its most recent fiscal years, as set
forth in Section 1003(a) of the AMEX Company Guide. Select was afforded the
opportunity to submit a plan of compliance to the Exchange and on May 28, 2002
the Company presented its plan to the Exchange. On July 26, 2002, the Exchange
notified Select that it accepted the Company`s plan of compliance and granted
the Company an extension of time to regain compliance with the continued listing
standards. Select will be subject to periodic review by Exchange Staff during
the extension period. Failure to make progress consistent with the plan or to
regain compliance with the continued listing standards by the end of the
extension period could result in the Company being delisted from the American
Stock Exchange.
"We are pleased to have received this notice of extension from AMEX," said Craig
Sibley, President and CEO. "This is another positive step forward in returning
Select to a stable and progressive status."
About Select:
Select Therapeutics Inc. is a drug development company engaged in the
development of novel, targeted therapeutic entities for the treatment of cancers
and infectious diseases. The Company is developing its proprietary, targeted
cancer therapeutic agent, VeroPulse(TM), for the treatment of certain cancers,
and also its proprietary targeted therapeutic vaccine technologies (Activate(TM)
and VeroVax(TM) for the treatment of cancers and infectious diseases. In
December 2001, Select Therapeutics Inc. terminated its joint venture, Cell
Science Therapeutics, and resumed an independent path for corporate and
technological development.
Certain of the statements contained in this news release may be considered
forward-looking statements. To the extent that any of the statements contained
herein are forward-looking, such statements are based on current expectations
and are subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. We caution investors that there can be no assurance that actual
results or business conditions will not differ materially from those projected
or suggested in such forward-looking statements as a result of various factors,
including, but not limited to, Select`s need for and ability to obtain
additional capital, the possible impairment of, or inability to obtain,
intellectual property rights and the cost of obtaining such rights from third
parties and dependence on third parties to research, develop, manufacture and
sell any products developed.
Craig Sibley
Select Therapeutics
617-989-0050
Schaut Sie Euch mal an - Restrukturierung wurde bereits genehmigt!!!
Aktuell 0,15$ - könnten sehr schnell Richtung 0,3-0,5$ gehen!
MfG
Star Ikone 2
Die Meldung:
Select Therapeutics Inc. Receives Notification of American Stock Exchange Acceptance of
Plan of Compliance
BOSTON, Aug 1, 2002 /PRNewswire-FirstCall via COMTEX/ -- Select Therapeutics
Inc. (Amex: XZL), today announced that the American Stock Exchange ("AMEX" or
the "Exchange") has accepted Select`s plan of compliance and that the Company
has received a listing extension to regain compliance with AMEX`s listing
standards on or before December 31, 2003, subject to periodic review by the
Exchange.
On April 26, 2002, Select received notice from the AMEX Staff indicating that,
as of the date of the letter, the Company had fallen below the continued
listings standards of the Exchange due to stockholders equity below $2 million
dollars and sustained losses in two of its most recent fiscal years, as set
forth in Section 1003(a) of the AMEX Company Guide. Select was afforded the
opportunity to submit a plan of compliance to the Exchange and on May 28, 2002
the Company presented its plan to the Exchange. On July 26, 2002, the Exchange
notified Select that it accepted the Company`s plan of compliance and granted
the Company an extension of time to regain compliance with the continued listing
standards. Select will be subject to periodic review by Exchange Staff during
the extension period. Failure to make progress consistent with the plan or to
regain compliance with the continued listing standards by the end of the
extension period could result in the Company being delisted from the American
Stock Exchange.
"We are pleased to have received this notice of extension from AMEX," said Craig
Sibley, President and CEO. "This is another positive step forward in returning
Select to a stable and progressive status."
About Select:
Select Therapeutics Inc. is a drug development company engaged in the
development of novel, targeted therapeutic entities for the treatment of cancers
and infectious diseases. The Company is developing its proprietary, targeted
cancer therapeutic agent, VeroPulse(TM), for the treatment of certain cancers,
and also its proprietary targeted therapeutic vaccine technologies (Activate(TM)
and VeroVax(TM) for the treatment of cancers and infectious diseases. In
December 2001, Select Therapeutics Inc. terminated its joint venture, Cell
Science Therapeutics, and resumed an independent path for corporate and
technological development.
Certain of the statements contained in this news release may be considered
forward-looking statements. To the extent that any of the statements contained
herein are forward-looking, such statements are based on current expectations
and are subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. We caution investors that there can be no assurance that actual
results or business conditions will not differ materially from those projected
or suggested in such forward-looking statements as a result of various factors,
including, but not limited to, Select`s need for and ability to obtain
additional capital, the possible impairment of, or inability to obtain,
intellectual property rights and the cost of obtaining such rights from third
parties and dependence on third parties to research, develop, manufacture and
sell any products developed.
Craig Sibley
Select Therapeutics
617-989-0050
Das es noch oben gehen kann, kann ich nicht ausschließen! Aber der Umsatz ist doch sehr niedrig!!!!
Schau dir lieber mal FINX an!!!
ne ne da finde ich select schon besser als finx auf alle fälle zumal select nicht an OTC ist
Umsätze gestern erstmals angestiegen:
SELECT THERAPEUTICS ( WKN 937075 )
Es deutet sich an, dass das Restrukturierungsprogramm voll greift!
Achtet auf die Firma, gestern wurde Widerstand bei 0,13$ genommen.
Auch in Deutschland handelbar, dürften so um 0,15€. eröffnen.
Einsteigen bis 0,2€. mit möglichem KZ 0,4-0,5€.
Es siehr sehr gut aus!
MfG
Star Ikone 2
SELECT THERAPEUTICS ( WKN 937075 )
Es deutet sich an, dass das Restrukturierungsprogramm voll greift!
Achtet auf die Firma, gestern wurde Widerstand bei 0,13$ genommen.
Auch in Deutschland handelbar, dürften so um 0,15€. eröffnen.
Einsteigen bis 0,2€. mit möglichem KZ 0,4-0,5€.
Es siehr sehr gut aus!
MfG
Star Ikone 2
Bin mal gespannt, ob man überhaupt noch zu 0,15€ reinkommt!
Achtet auf SELECT T. 937075!
MfG
SI 2
Achtet auf SELECT T. 937075!
MfG
SI 2
Es geht gerade erst los!
Einsteigen!
MfG
SI 2
Einsteigen!
MfG
SI 2
SELECT THERAPEUTICS WKN 937075 wird weiter durchstarten!
Achtet auf die USA - rechne zur Eröffnung mit 0,2$!
Noch ist bei uns in Deutschland der Einstieg billig. Das Restrukturierungskonzept greift voll, Finanzmittel sind gefunden!
Hier lauert eine 100% Chance!
MfG
SI 2
Achtet auf die USA - rechne zur Eröffnung mit 0,2$!
Noch ist bei uns in Deutschland der Einstieg billig. Das Restrukturierungskonzept greift voll, Finanzmittel sind gefunden!
Hier lauert eine 100% Chance!
MfG
SI 2
ähhh ... meint Ihr den Wert der gerade in USA verprügelt wird?
heute ist ja richtig was los
Hallo StarIkone2,
was ist mit Select Therapeutics passiert?
Irren ist menschlich! Oder hast Du einen Dummen gesucht, der Deine Stücke abnimmt?!
Viel Glück!
was ist mit Select Therapeutics passiert?
Irren ist menschlich! Oder hast Du einen Dummen gesucht, der Deine Stücke abnimmt?!
Viel Glück!
starlkone2 hat umsonst die Aktie gepusht. Sieht so aus, als ob Select nun endgültig das Geld ausgegangen ist. Mehr als diese ältere Nachricht von FinanzNachrichten vom 17.10.02 kann ich nicht finden.
"Select Therapeutics Inc. announced today that the American Stock Exchange has issued a Halt Trading order on the Company`s Common Stock. The proximate cause for this action is that the Company is late in filing its 10- KSB for the previous Fiscal Year, because it currently lacks the resources to prepare and make this filling. Select Therapeutics is commencing discussions with Amex representatives to determine how the Company may return its stock to trading status."
Gruß elimu
"Select Therapeutics Inc. announced today that the American Stock Exchange has issued a Halt Trading order on the Company`s Common Stock. The proximate cause for this action is that the Company is late in filing its 10- KSB for the previous Fiscal Year, because it currently lacks the resources to prepare and make this filling. Select Therapeutics is commencing discussions with Amex representatives to determine how the Company may return its stock to trading status."
Gruß elimu
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
177 | ||
120 | ||
78 | ||
58 | ||
57 | ||
56 | ||
54 | ||
51 | ||
44 | ||
40 |
Wertpapier | Beiträge | |
---|---|---|
38 | ||
31 | ||
30 | ||
29 | ||
27 | ||
27 | ||
26 | ||
23 | ||
22 | ||
20 |